Back to results
US 6,395,276 B1Granted
Immunotoxins directed against malignant cells
AssigneeImmunomedics, Inc.
InventorsSusanna M. Rybak, Dianne L. Newton, David M. Goldenberg
Life of this patent
Estimating the term…
Abstract
The present invention relates to immunotoxins, that effectively kill malignant cells having a given surface marker and nucleic acid constructs encoding them. These reagents comprise a toxic moiety that is derived from a Rana pipiens protein having ribonucleolytic activity linked to an antibody capable of specific binding with a chosen tumor cell.
Claims8
A method of killing malignant B cells comprising:
- contacting a population of human malignant B cells with a selective cytotoxic reagent comprising an onc protein having measurable ribonucleolytic activity covalently linked to an antibody directed against a cell surface marker present on the B cells, wherein the cytotoxic reagent is at least 100 times more cytotoxic to target cells bearing a B cell marker than a comparison reagent comprised of the same antibody joined to the human non-toxic RNase eosinophil-derived neurotoxin (EDN);
- and thereby killing the human malignant B cells.
Dependencies are inferred from the claim text.